[Effect of enape combined with nebilet in hypertension].
Patients with stage II hypertensive disease have been shown to derive apparent benefit from treatment with a combination of the beta-adrenoblocker nebivolol and inhibitor of the angiotensin-converting enzyme enap that was evidenced by improvement in hemodynamics, in echocardiographic characteristics promoting a decline in the activity of the basic enzyme of the tissue formation angiotensin II chimase and an increase in the level of its most important inhibitor alpha-2-macroglobulin.
Gol'drin
E N
EN
Samokhina
L M
LM
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D001578:Benzopyrans / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004452:Echocardiography; D004656:Enalapril / Q000008:administration & dosage / Q000627:therapeutic use*; D010450:Endopeptidases / Q000378:metabolism; D004983:Ethanolamines / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006439:Hemodynamics / Q000187:drug effects / Q000502:physiology; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D008297:Male; D000068577:Nebivolol; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D001578:Benzopyrans; D004983:Ethanolamines; D000068577:Nebivolol; D004656:Enalapril; D010450:Endopeptidases